US Cancer Vaccine Market Outlook 2022
Cancer is one of the major health issues faced by the countries across the globe. The researchers are engaged in developing various drugs for the prevention and treatment of the disease. Cancer vaccine is one such example. Since their inception, cancer vaccines were considered as high potential method for preventing and treating cancer. Till date, the vaccines have not been able to achieve the expected sales due to high cost and negative results in clinical trials. However, with launch of new cancer vaccines, such as Imlygic by Amgen; and increasing awareness of people regarding these vaccines, the market is expected to grow.
The US is largest market for cancer vaccines. The growth of the US cancer vaccine market is driven by increasing cancer incidence in the country, rising awareness, and strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides detailed analysis of the market. This report covers the present scenario and the growth prospects of US cancer vaccine market for the period 2015-2022. It also covers the drivers, restraints hampering the growth of the market, and future opportunities. Moreover, the report provides the global sales of various cancer vaccines from 2013-2015.
On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. Currently, HPV related cancer vaccines occupy the largest share in the US market.
On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounts for the largest share in 2016. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Amongst the various research studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as TV4010 and GV1001, having entered phase 3 trials.
The report also provides market share analysis by key players. Merck and GSK are expected to continue to be undisputed market leaders in the cancer vaccine market. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.
The last section of the report discusses about the key players in the US cancer vaccine market. A brief business overview and financial information about each of these players has been provided in the report. Moreover, this report will help the reader to gain crucial insight into the key players’ performances and strategies for growth. Conclusively, the research will prove to be a useful resource for all debut makers in US cancer vaccine industry and potential investors.
The US is largest market for cancer vaccines. The growth of the US cancer vaccine market is driven by increasing cancer incidence in the country, rising awareness, and strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides detailed analysis of the market. This report covers the present scenario and the growth prospects of US cancer vaccine market for the period 2015-2022. It also covers the drivers, restraints hampering the growth of the market, and future opportunities. Moreover, the report provides the global sales of various cancer vaccines from 2013-2015.
On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. Currently, HPV related cancer vaccines occupy the largest share in the US market.
On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounts for the largest share in 2016. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Amongst the various research studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as TV4010 and GV1001, having entered phase 3 trials.
The report also provides market share analysis by key players. Merck and GSK are expected to continue to be undisputed market leaders in the cancer vaccine market. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.
The last section of the report discusses about the key players in the US cancer vaccine market. A brief business overview and financial information about each of these players has been provided in the report. Moreover, this report will help the reader to gain crucial insight into the key players’ performances and strategies for growth. Conclusively, the research will prove to be a useful resource for all debut makers in US cancer vaccine industry and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. CANCER STATISTICS BY DEMOGRAPHICS
3.1 Prevalence, Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. CANCER VACCINES MARKET OUTLOOK
5.1 Key Product Analysis
5.1.1 Provenge
5.1.1.1 Market Analysis
5.1.2 T-Vec/Imlygic
5.1.2.1 Market Analysis
5.1.3 HPV Vaccine
5.1.3.1 Gardasil
5.1.3.1.1 Market Analysis
5.1.3.2 Cervarix
5.1.3.2.1 Market Analysis
5.1.4 HBV Vaccines
5.1.4.1 Engerix-B
5.1.4.1.1 Market Analysis
5.1.4.2 Recombivax HB
5.1.4.2.1 Market Analysis
5.1.4.3 Pediarix/ Infanrix
5.1.4.3.1 Market Analysis
6. CANCER VACCINES MARKET BY CANCER TYPE
7. CANCER VACCINE MARKET BY APPLICATION
8. POTENTIAL CANCER VACCINE CANDIDATES: AN OPPORTUNITY ASSESSMENT
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US PATENT ANALYSIS
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. REGULATORY ENVIRONMENT
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials
10.2.1.1 Patient Population
10.2.1.2 Monitoring the Immune Response
10.2.1.3 Biomarkers as Evidence of Efficacy
10.2.1.4 Adjuvants Used to Stimulate Immune Response
10.2.1.5 Multi-antigen Vaccines
10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
10.2.1.7 Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials
10.2.2.1 Starting Dose and Dosing Schedule
10.2.2.2 Booster and Maintenance Therapy
10.2.2.3 Dose Escalation
10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials
10.2.3.1 Safety Profile from Early Phase Clinical Trials
10.2.3.2 Endpoints
10.2.3.3 Statistical Issues
10.2.3.4 Control Issues
10.2.3.5 Delayed Vaccine Effect
10.2.3.6 Autologous Vaccine Trials
10.2.3.7 Accelerated Approval Regulations
11. COMPETITIVE LANDSCAPE
12. COMPANY PROFILES
12.1 Merck & Co.
12.2 GlaxoSmithKline plc
12.3 Dendreon (A Subsidiary of Valeant Pharmaceuticals)
12.4 Amgen Inc.
2. RESEARCH METHODOLOGY
3. CANCER STATISTICS BY DEMOGRAPHICS
3.1 Prevalence, Incidences and Mortality
3.2 Leading States by Incidences
3.3 Leading Cancers by Incidences
3.3.1 Male Cancer Incidences
3.3.2 Female Cancer Incidences
3.3.3 Children Cancer Incidences
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Rising Cancer Incidences
4.1.2 Ability to Reduce Healthcare Expenditure
4.1.3 Rising Awareness
4.1.4 Patient Assistance Programs
4.1.5 Government Initiatives
4.1.6 Strong Pipeline
4.1.7 Technological Advancements
4.2 Restraints
4.2.1 High Cost of Cancer Vaccines
4.2.2 Side Effects of Cancer Vaccines
4.2.3 Vaccine Supply Shortages
4.2.4 Insurance Issues Related to Cancer Vaccination
4.3 Opportunities
4.3.1 Therapeutic Cancer Vaccines
4.3.2 Adjuvant Cancer Vaccines
5. CANCER VACCINES MARKET OUTLOOK
5.1 Key Product Analysis
5.1.1 Provenge
5.1.1.1 Market Analysis
5.1.2 T-Vec/Imlygic
5.1.2.1 Market Analysis
5.1.3 HPV Vaccine
5.1.3.1 Gardasil
5.1.3.1.1 Market Analysis
5.1.3.2 Cervarix
5.1.3.2.1 Market Analysis
5.1.4 HBV Vaccines
5.1.4.1 Engerix-B
5.1.4.1.1 Market Analysis
5.1.4.2 Recombivax HB
5.1.4.2.1 Market Analysis
5.1.4.3 Pediarix/ Infanrix
5.1.4.3.1 Market Analysis
6. CANCER VACCINES MARKET BY CANCER TYPE
7. CANCER VACCINE MARKET BY APPLICATION
8. POTENTIAL CANCER VACCINE CANDIDATES: AN OPPORTUNITY ASSESSMENT
8.1 Prophylactic Vaccine
8.2 Therapeutic Vaccine
8.2.1 Prostate Cancer
8.2.2 Breast Cancer
8.2.3 Lung Cancer
8.2.4 Colorectal Cancer
9. US PATENT ANALYSIS
9.1 Patents by Year
9.2 Patents by Category
9.2.1 Utility Patents
9.2.2 Design Patents
9.2.3 Plant Patents
9.3 Patents by Company
9.4 Patents by Assignee Type
9.4.1 By Assignee Name
9.4.2 By Assignee State
10. REGULATORY ENVIRONMENT
10.1 Vaccine Approval Process
10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
10.2.1 Considerations for both Early and Late Phase Clinical Trials
10.2.1.1 Patient Population
10.2.1.2 Monitoring the Immune Response
10.2.1.3 Biomarkers as Evidence of Efficacy
10.2.1.4 Adjuvants Used to Stimulate Immune Response
10.2.1.5 Multi-antigen Vaccines
10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
10.2.1.7 Concomitant and Subsequent Therapies
10.2.2 Considerations for Early Phase Clinical Trials
10.2.2.1 Starting Dose and Dosing Schedule
10.2.2.2 Booster and Maintenance Therapy
10.2.2.3 Dose Escalation
10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
10.2.3 Considerations for Late Phase Clinical Trials
10.2.3.1 Safety Profile from Early Phase Clinical Trials
10.2.3.2 Endpoints
10.2.3.3 Statistical Issues
10.2.3.4 Control Issues
10.2.3.5 Delayed Vaccine Effect
10.2.3.6 Autologous Vaccine Trials
10.2.3.7 Accelerated Approval Regulations
11. COMPETITIVE LANDSCAPE
12. COMPANY PROFILES
12.1 Merck & Co.
12.2 GlaxoSmithKline plc
12.3 Dendreon (A Subsidiary of Valeant Pharmaceuticals)
12.4 Amgen Inc.
LIST OF FIGURES:
Figure 3-1: Cancer Incidences (Million), 2015-2022
Figure 3-2: Cancer Mortality (Million), 2015-2022
Figure 3-3: Incidences by Type of Cancer (%), 2016
Figure 3-4: States with Highest Cancer Incidences, 2015
Figure 5-1: Share of US in Global Cancer Vaccine Market (%), 2016
Figure 5-2: US - Cancer Vaccine Market by Product Type (%), 2016
Figure 5-3: Global - Provenge Market (Million US$), 2013-2015
Figure 5-4: Share of US in Global Imlygic Sales (%), 2015
Figure 5-5: Global - Gardasil Market (Million US$), 2013-2015
Figure 5-6: US - Gardasil Market (Million US$), 2013-2015
Figure 5-7: Share of US in Global Gardasil Sales (%), 2015
Figure 5-8: Global - Cervarix Market (Million US$), 2013-2015
Figure 5-9: US - Cervarix Market (Million US$), 2013-2015
Figure 5-10: Share of US in Global Cervarix Sales (%), 2015
Figure 5-11: Global - Engerix-B Market (Million US$), 2013-2015
Figure 5-12: US - Engerix-B Market (Million US$), 2013-2015
Figure 5-13: Share of US in Global Engerix-B Sales (%), 2015
Figure 5-14: Global - Recombivax HB Market (Million US$), 2013-2015
Figure 5-15: US - Recombivax HB Market (Million US$), 2013-2015
Figure 5-16: Share of US in Global Recombivax HB Sales (%), 2015
Figure 5-17: Global - Pediarix/Infanrix Market (Million US$), 2013-2015
Figure 5-18: US - Pediarix/ Infanrix Market (Million US$), 2013-2015
Figure 5-19: Share of US in Global Pediarix/Infanrix Sales (%), 2015
Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2016
Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2015-2022
Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2015-2022
Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2015-2022
Figure 7-1: US - Cancer Vaccine Market by Application (%), 2016
Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2015-2022
Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2015-2022
Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2016
Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2016
Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2016
Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2015
Figure 12-1: Merck & Co. - Breakup of Revenue by Segment (%), 2015
Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Segment (%), 2015
Figure 12-3: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Segment (%), 2015
Figure 3-1: Cancer Incidences (Million), 2015-2022
Figure 3-2: Cancer Mortality (Million), 2015-2022
Figure 3-3: Incidences by Type of Cancer (%), 2016
Figure 3-4: States with Highest Cancer Incidences, 2015
Figure 5-1: Share of US in Global Cancer Vaccine Market (%), 2016
Figure 5-2: US - Cancer Vaccine Market by Product Type (%), 2016
Figure 5-3: Global - Provenge Market (Million US$), 2013-2015
Figure 5-4: Share of US in Global Imlygic Sales (%), 2015
Figure 5-5: Global - Gardasil Market (Million US$), 2013-2015
Figure 5-6: US - Gardasil Market (Million US$), 2013-2015
Figure 5-7: Share of US in Global Gardasil Sales (%), 2015
Figure 5-8: Global - Cervarix Market (Million US$), 2013-2015
Figure 5-9: US - Cervarix Market (Million US$), 2013-2015
Figure 5-10: Share of US in Global Cervarix Sales (%), 2015
Figure 5-11: Global - Engerix-B Market (Million US$), 2013-2015
Figure 5-12: US - Engerix-B Market (Million US$), 2013-2015
Figure 5-13: Share of US in Global Engerix-B Sales (%), 2015
Figure 5-14: Global - Recombivax HB Market (Million US$), 2013-2015
Figure 5-15: US - Recombivax HB Market (Million US$), 2013-2015
Figure 5-16: Share of US in Global Recombivax HB Sales (%), 2015
Figure 5-17: Global - Pediarix/Infanrix Market (Million US$), 2013-2015
Figure 5-18: US - Pediarix/ Infanrix Market (Million US$), 2013-2015
Figure 5-19: Share of US in Global Pediarix/Infanrix Sales (%), 2015
Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2016
Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2015-2022
Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2015-2022
Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2015-2022
Figure 7-1: US - Cancer Vaccine Market by Application (%), 2016
Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2015-2022
Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2015-2022
Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2016
Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016
Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2016
Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2016
Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2015
Figure 12-1: Merck & Co. - Breakup of Revenue by Segment (%), 2015
Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Segment (%), 2015
Figure 12-3: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Segment (%), 2015
LIST OF TABLES:
Table 3-1: Top 10 Cancer Incidences in Males (2015)
Table 3-2: Top 10 Cancer Incidences in Females (2015)
Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2015)
Table 4-1: US - Cancer Incidences (Million), 2015 & 2020
Table 5-1: Global - Cancer Vaccine Market (Million US$), 2015-2022
Table 5-2: US - Cancer Vaccine Market (Million US$), 2015-2022
Table 8-1: Cancers with High Linkage to Virus and Bacteria
Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
Table 12-1: Merck & Co. - Key Financials (Million US$), 2013-2015
Table 12-2: Merck - Product Portfolio
Table 12-3: Merck - Cancer Vaccines in Pipeline
Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
Table 12-5: GlaxoSmithKline - Product Portfolio
Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 12-7: Valeant Pharmaceuticals International, Inc. - Key Financials (Million US$), 2013-2015
Table 12-8: Dendreon - Product Portfolio
Table 12-9: Amgen Inc. - Key Financials (Million US$), 2013-2015
Table 12-10: Amgen Inc. - Product Portfolio
Table 3-1: Top 10 Cancer Incidences in Males (2015)
Table 3-2: Top 10 Cancer Incidences in Females (2015)
Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2015)
Table 4-1: US - Cancer Incidences (Million), 2015 & 2020
Table 5-1: Global - Cancer Vaccine Market (Million US$), 2015-2022
Table 5-2: US - Cancer Vaccine Market (Million US$), 2015-2022
Table 8-1: Cancers with High Linkage to Virus and Bacteria
Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
Table 12-1: Merck & Co. - Key Financials (Million US$), 2013-2015
Table 12-2: Merck - Product Portfolio
Table 12-3: Merck - Cancer Vaccines in Pipeline
Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
Table 12-5: GlaxoSmithKline - Product Portfolio
Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
Table 12-7: Valeant Pharmaceuticals International, Inc. - Key Financials (Million US$), 2013-2015
Table 12-8: Dendreon - Product Portfolio
Table 12-9: Amgen Inc. - Key Financials (Million US$), 2013-2015
Table 12-10: Amgen Inc. - Product Portfolio
